Natera, Inc. (NASDAQ:NTRA) Baird Global Healthcare Conference 2025 September 9, 2025 8:30 AM EDT
Company Participants
Mike Brophy – Chief Financial Officer
Steve Chapman – CEO & Director
Conference Call Participants
Catherine Ramsey – Robert W. Baird & Co. Incorporated, Research Division
Presentation
Catherine Ramsey
Senior Research Analyst
All right, everyone. Welcome, and good morning. I’m Catherine Schulte. I cover life sciences and diagnostics here at Baird. Very excited to have Natera here with us today. From the company, we have the CEO, Steve Chapman; CFO, Mike Brophy. So Steve, Mike, thanks so much for joining us.
Mike Brophy
Chief Financial Officer
Thanks for having us.
Steve Chapman
CEO & Director
Yes, thanks for having us.
Question-and-Answer Session
Catherine Ramsey
Robert W. Baird & Co. Incorporated, Research Division
And if anyone has any questions during the session, you can e-mail them to session1@rwbaird.com, and I will pass them along. So I guess, first, I wanted to start on Signatera. You had another incredible quarter, record sequential volume growth. You upgraded the volume growth outlook going forward. Can you just talk through kind of some of the — what’s driving some of that strength that you’re seeing?
Steve Chapman
CEO & Director
Yes. So we’re seeing a lot of interest in Signatera broadly. And I really think that there’s been sort of a change in the physician mentality over the past year. There’s just — you go to the conferences, you go to ASCO, ctDNA and MRD testing is everywhere. Tons of presentations, tons of talks, tons of interest side conversations. And so we’re seeing this really tidal wave, I think, of interest in MRD testing.
And we’re right at the front of that as the market leader with the vast majority of market share. And it’s really being driven, I think, by the significant amount
#Natera #NTRA #Presents #Baird #Global #Healthcare #Conference #Transcript